9 August 2022
24 June 2022
READ MOREBiolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine
12 May 2022
READ MOREAkston Biosciences Doses First Participants in Phase II Clinical Trial for Shelf-Stable COVID-19 Booster
12 April 2022
READ MOREAkston Biosciences CEO to Present at the World Vaccine Congress
7 April 2022
READ MOREAkston Biosciences Doses First Volunteers in Phase II/III Clinical Trial of Low Cost, Shelf Stable COVID-19 Vaccine
31 March 2022
READ MOREAkston Biosciences Receives Regulatory Approval for Phase II Clinical Trial for Shelf-Stable COVID-19 Vaccine Booster
17 March 2022
READ MOREAkston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries
8 February 2022
READ MOREAkston Biosciences Announces Publication in Vaccine of Positive Data for a Room Temperature Protein Subunit COVID-19 Vaccine
21 December 2021
READ MOREAkston Biosciences Announces Positive Top-Line Data from Phase II Study of COVID-19 Vaccine in the Netherlands
19 November 2021